For patients with NSCLC with non-classical driver mutation alterations (atypical EGFR, BRAF nonV600E, etc), what resources do you utilize to determine likelihood that tumor will be sensitive to targeted therapies?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Roswell Park Comprehensive Cancer Center
Answered on
Resources to look up information:
1. OncoKB
2. ClinVar
3. The Jackson Laboratory The Clinical Knowledgebase (free version with limited # of genes, subscription required for a larger database)
Join for free or sign in to see the full answer